Patents Represented by Attorney, Agent or Law Firm Michael J. Ward
  • Antibacterial compounds
    Patent number: 7737159
    Abstract: Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 15, 2010
    Assignee: Abbott Laboratories
    Inventors: David D. Anderson, Bruce A. Beutel, Curt S. Cooper, Yu-Gui Gu, Mira M. Hinman, Douglas M. Kalvin, Robert F. Keyes, Xenia B. Searle, Rolf Wagner
  • Prodrugs of HIV protease inhibitors
    Patent number: 7718633
    Abstract: A compound of the formula is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions for inhibiting HIV protease activity and treating HIV infection are also disclosed.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: May 18, 2010
    Assignee: Abbott Laboratories
    Inventors: David A. DeGoey, William J. Flosi, David J. Grampovnik, Larry L. Klein, Dale J. Kempf, Xiu C. Wang
  • Naphthyridine-based antibacterial compositions
    Patent number: 7632946
    Abstract: Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: December 15, 2009
    Assignee: Abbott Laboratories
    Inventors: Mira M Hinman, Teresa A. Rosenberg, Rolf Wagner
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
    Patent number: 7547678
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: June 16, 2009
    Assignee: Abbott Laboratories
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
    Patent number: 7320961
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: January 22, 2008
    Assignee: Abbott Laboratories
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 6933311
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: August 23, 2005
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
    Patent number: 6831193
    Abstract: Compounds of formula (I) are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • Diazabicyclic central nervous system active agents
    Patent number: 6809105
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: October 26, 2004
    Assignee: Abbott Laboratories
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Pace, Kevin B. Sippy
  • Methods and reagents for cyanide-free determination of hemoglobin and leukocytes in whole blood
    Patent number: 6740527
    Abstract: Cyanide-free reagents for the determination of hemoglobin and leukocytes present in a blood sample comprise an aqueous solutions of at least one quaternary ammonium salt, preferably selected from the group of alkyltrimethylammonium salts, alkyldimethylbenzylammonium salts or alkylpyridium salts consisting of tetradecyltrimethyl ammonium bromide (TTAB), dodecyltrimethyl ammonium chloride, cetyltrimethyl ammonium bromide, hexadecyltrimethyl ammonium bromide and benzalkonium chlorides, and hydroxylamine salts, especially hydrochloride, sulfate and phosphates and other acid salts. The method involves mixing the reagent with a diluent-diluted blood sample, presenting it to an absorbance spectrophotometer and measuring the resulting optical density as an indicator of hemoglobin concentration. This cyanide-free reagent could be used solely for hemoglobin determinations, or, it can also be used in leukocyte counting and sizing using hematology instrumentation.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: May 25, 2004
    Assignee: Abbott Laboratories
    Inventors: Show-Chu Wong, Sylvia Khoo
  • Potassium channel openers
    Patent number: 6645968
    Abstract: Compounds of formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: November 11, 2003
    Assignee: Abbott Laboratories
    Inventors: Robert J. Altenbach, Hao Bai, Jorge D. Brioni, William A. Carroll, Murali Gopalakrishnan, Robert J. Gregg, Mark W. Holladay, Peggy P. Huang, John F. Kincaid, Michael E. Kort, Philip R. Kym, John K. Lynch, Arturo Perez-Medrano, Henry Q. Zhang
  • Pyrano, piperidino, and thiopyrano compounds and methods of use
    Patent number: 6642222
    Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: November 4, 2003
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
  • Potassium channel openers
    Patent number: 6593335
    Abstract: Compounds having the formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: July 15, 2003
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Yiyuan Chen, Mark W. Holladay, Michael E. Kort, Philip R. Kym, James P. Sullivan, Rui Tang, Lin Yi, Henry Q. Zhang, Irene Drizin
  • Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
    Patent number: 6538004
    Abstract: Compounds of formula I are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: March 25, 2003
    Assignee: Abbott Laboratories
    Inventors: Irene Drizin, Robert J. Altenbach, William A. Carroll
  • Tricyclic dihydropyrimidine potassium channel openers
    Patent number: 6538000
    Abstract: Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: March 25, 2003
    Assignee: Abbott Laboratories
    Inventors: Mark W. Holladay, William A. Carroll, Irene Drizin, Lin Yi, Henry Q. Zhang
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Patent number: 6525053
    Abstract: The present invention describes pyridazione compounds having the formula (I), which are cyclooxygenase (COX) inhibitors The compounds are selective inhibitors of cyclooxygenase-2-(COX-2), which is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDS).
    Type: Grant
    Filed: August 20, 1998
    Date of Patent: February 25, 2003
    Assignee: Abbott Laboratories
    Inventor: Lawrence A. Black
  • Process for producing cross-linked polyallylamine hydrochloride
    Patent number: 6525113
    Abstract: The present invention relates to a process for preparing a cross-linked pollyallylamine hydrochloride. The process involves mixing polyallylamine hydrochloride, water, a hydroxide or alkoxide, and a water-miscible organic solvent or co-solvents, to a reaction mixture and adding a cross-linking agent to the reaction mixture to form a cross-linked polyallylamine.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: February 25, 2003
    Assignee: Abbott Laboratories
    Inventors: Russell C. Klix, Jufang H. Barkalow, William T. Monte
  • Cyclopentanone dihydropyridine compounds useful as potassium channel openers
    Patent number: 6518279
    Abstract: Compounds of formula I are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: February 11, 2003
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Yiyuan Chen, Irene Drizin, James F. Kerwin, Jimmie L. Moore
  • 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
    Patent number: 6515013
    Abstract: Compounds of formula I are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands. Also disclosed are histamine-3 receptor ligand compositions and methods of antagonizing or agonizing histamine-3 receptors.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: February 4, 2003
    Assignee: Abbott Laboratories
    Inventors: Youssef L. Bennani, Ramin Faghih, Wesley J. Dwight, Anil Vasudevan, Scott E. Conner
  • Imidazoles and related compounds as &agr;1A agonists
    Patent number: 6503935
    Abstract: Compounds having formula I: are useful in treating diseases prevented by or ameliorated with &agr;1A agonists. Also disclosed are &agr;1A agonist compositions and a method of activating &agr;1 adrenoceptors in a mammal.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: January 7, 2003
    Assignee: Abbott Laboratories
    Inventors: Robert J. Altenbach, Michael D. Meyer, James F. Kerwin, Jr., Mark W. Holladay, Albert Khilevich, Teodozyj Kolasa, Jeffrey Rohde, William A. Carroll
  • Aminal diones as potassium channel openers
    Patent number: 6495576
    Abstract: Compounds of formula (I) may be useful in treating diseases prevented by or ameliorated with potassium channel openers.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: December 17, 2002
    Assignee: Abbott Laboratories
    Inventors: Michael E. Kort, Robert J. Gregg, William A. Carroll, Arturo Perez Medrano, Jürgen Dinges, Fatima Z. Basha